Evidence map›Paper›PMID 26378562›Full record

ReviewInternational journal of environmental research and public health2015

Fire Blight Control: The Struggle Goes On. A Comparison of Different Fire Blight Control Methods in Switzerland with Respect to Biosafety, Efficacy and Durability.

Michele Gusberti, Urs Klemm, Matthias S Meier, Monika Maurhofer, Isabel Hunger-Glaser

Open access · goldAbstract readComparative StudyReview
In one paragraph

Review in International journal of environmental research and public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.

0numbers the graph read from it
0cells of the map it votes in
23citing papers in PubMed
5.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

23 citing papers in PubMed, 68 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Genome-Wide Identification of theInternational journal of molecular sciences · 2025
    Article
  5. APlants (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Article
  9. First EuropeanBiology · 2024
    Article
  10. An app for apples: Citizen-led mapping of fire blight in Central Asia.Journal of plant pathology : an international journal of the Italian Phytopathological Society · 2024
    Article
  11. Article
  12. Article
  13. Control ofPlants (Basel, Switzerland) · 2022
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Michele GusbertiInstitute of Integrative Biology Zurich, Plant Pathology Group, Swiss Federal Institute of Technology, Zurich CH-8092, Switzerland. michele.gusberti@usys.ethz.ch.
Urs KlemmSwiss Expert Committee for Biosafety, Bern CH-3003, Switzerland. info@ursklemm.ch.
Matthias S MeierSwiss Expert Committee for Biosafety, Bern CH-3003, Switzerland. matthias.meier@fibl.org.
Monika MaurhoferInstitute of Integrative Biology Zurich, Plant Pathology Group, Swiss Federal Institute of Technology, Zurich CH-8092, Switzerland. monika.maurhofer@usys.ethz.ch.
Isabel Hunger-GlaserSwiss Expert Committee for Biosafety, Bern CH-3003, Switzerland. info@ursklemm.ch.
Swiss Expert Committee for Biosafety · CHForschungsinstitut für Biologischen Landbau · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fire blight (FB), caused by Erwinia amylovora, is one of the most important pome fruit pathogens worldwide. To control this devastating disease, various chemical and biological treatments are commonly applied in Switzerland, but they fail to keep the infection at an acceptable level in years of heavy disease pressure. The Swiss authorities therefore currently allow the controlled use of the antibiotic streptomycin against FB in years that are predicted to have heavy infection periods, but only one treatment per season is permitted. Another strategy for controlling Erwinia is to breed resistant/tolerant apple cultivars. One way of accelerating the breeding process is to obtain resistant cultivars by inserting one or several major resistance genes, using genetic engineering. To date, no study summarizing the impact of different FB control measures on the environment and on human health has been performed. This study consequently aims to compare different disease-control measures (biological control, chemical control, control by antibiotics and by resistant/tolerant apple cultivars obtained through conventional or molecular breeding) applied against E. amylovora, considering different protection goals (protection of human health, environment, agricultural diversity and economic interest), with special emphasis on biosafety aspects. Information on each FB control measure in relation to the specified protection goal was assessed by literature searches and by interviews with experts. Based on our results it can be concluded that the FB control measures currently applied in Switzerland are safe for consumers, workers and the environment. However, there are several gaps in our knowledge of the human health and environmental impacts analyzed: data are missing (1) on long term studies on the efficacy of most of the analyzed FB control measures; (2) on the safety of operators handling streptomycin; (3) on residue analyses of Equisetum plant extract, the copper and aluminum compounds used in apple production; and (4) on the effect of biological and chemical control measures on non-target fauna and flora. These gaps urgently need to be addressed in the near future.

Indexed as

Erwinia amylovoraMalusAnti-Bacterial AgentsFruitHumansPlant BreedingPlant DiseasesStreptomycinSwitzerlandAnti-Bacterial AgentsStreptomycinbiosafetybreedingdisease controlErwinia amylovoragenetic engineeringpesticides

Identifiers

PMID26378562
PMCPMC4586684
OpenAlexW2124154021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.